| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin … M Markman, BN Bundy, DS Alberts, JM Fowler, DL Clark-Pearson, ... Journal of clinical oncology 19 (4), 1001-1007, 2001 | 1286 | 2001 |
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study WE Winter III, GL Maxwell, C Tian, JW Carlson, RF Ozols, PG Rose, ... Journal of clinical oncology 25 (24), 3621-3627, 2007 | 1014 | 2007 |
| Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, ... Journal of Clinical Oncology 9 (3), 389-393, 1991 | 1012 | 1991 |
| Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues R Temple, SS Ellenberg Annals of internal medicine 133 (6), 455-463, 2000 | 1004 | 2000 |
| Ovarian cancer BT Hennessy, RL Coleman, M Markman The lancet 374 (9698), 1371-1382, 2009 | 926 | 2009 |
| Principles and practice of gynecologic oncology RR Barakat, M Markman, M Randall Lippincott Williams & Wilkins, 2009 | 926 | 2009 |
| Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers Y Xu, Z Shen, DW Wiper, M Wu, RE Morton, P Elson, AW Kennedy, ... Jama 280 (8), 719-723, 1998 | 875 | 1998 |
| The chemotherapy source book MC Perry Lippincott Williams & Wilkins, 2008 | 624 | 2008 |
| Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based … M Markman, PY Liu, S Wilczynski, B Monk, LJ Copeland, RD Alvarez, ... Journal of Clinical Oncology 21 (13), 2460-2465, 2003 | 529 | 2003 |
| Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer BTJ Hennessy, KM Timms, MS Carey, A Gutin, LA Meyer, DD Flake, ... Journal of Clinical Oncology 28 (22), 3570-3576, 2010 | 442 | 2010 |
| Paclitaxel in cancer therapy M Markman, TM Mekhail Expert opinion on pharmacotherapy 3 (6), 755-766, 2002 | 421 | 2002 |
| Role of nutritional status in predicting quality of life outcomes in cancer–a systematic review of the epidemiological literature CG Lis, D Gupta, CA Lammersfeld, M Markman, PG Vashi Nutrition journal 11, 1-18, 2012 | 407 | 2012 |
| Clinical features of hypersensitivity reactions to carboplatin M Markman, A Kennedy, K Webster, P Elson, G Peterson, B Kulp, ... Journal of Clinical Oncology 17 (4), 1141-1141, 1999 | 407 | 1999 |
| Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. M Markman, E Rowinsky, T Hakes, B Reichman, W Jones, JL Lewis Jr, ... Journal of Clinical Oncology 10 (9), 1485-1491, 1992 | 394 | 1992 |
| Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases SS Ellenberg, R Temple Annals of Internal Medicine 133 (6), 464-470, 2000 | 392 | 2000 |
| Second-line treatment of ovarian cancer M Markman, MA Bookman The oncologist 5 (1), 26-35, 2000 | 367 | 2000 |
| Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study HD Homesley, V Filiaci, M Markman, P Bitterman, L Eaton, LC Kilgore, ... Journal of Clinical Oncology 25 (5), 526-531, 2007 | 330 | 2007 |
| Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study D Tewari, JJ Java, R Salani, DK Armstrong, M Markman, T Herzog, ... Journal of Clinical Oncology 33 (13), 1460-1466, 2015 | 306 | 2015 |
| Intraperitoneal antineoplastic drug delivery: rationale and results M Markman The lancet oncology 4 (5), 277-283, 2003 | 299 | 2003 |
| Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study M Markman, J Blessing, SC Rubin, J Connor, P Hanjani, S Waggoner Gynecologic oncology 101 (3), 436-440, 2006 | 279 | 2006 |
